ATAI LIFE SCIENCES NV(NASDAQ:ATAI) stock News

ATAI Latest News, Press Relases and Analysis

All

Press Releases

13 days ago - By: Chartmill - Mentions: GTI SQNS ADAP QH ...

What's going on in today's pre-market session

15 days ago - By: Chartmill - Mentions: MSW RVSN CELC OPI ...

Top movers in Friday's after hours session

9 days ago - By: Yahoo Finance

H.C. Wainwright Lifts PT on Atai Life Sciences (ATAI) to $15 From $10

11 days ago - By: Benzinga - Mentions: LION LODE SRPT IONQ

This IonQ Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

12 days ago - By: Benzinga - Mentions: LODE IONQ QBTS

This Atai Life Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday

16 days ago - By: atai Life Sciences

Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia

16 days ago - By: atai Life Sciences

Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia

a month ago - By: Yahoo Finance

Aegis Capital Reaffirms Buy on Atai Life Sciences N.V. (ATAI) with $8 Target

a month ago - By: Yahoo Finance - Mentions: GS

Canaccord Genuity Lifts Atai Life Sciences N.V. (ATAI)’s Price Target To $12, Maintains Buy Rating

a month ago - By: FN Media Group LLC - Mentions: NYSE CMPS SAGE MNMD

Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032

a month ago - By: atai Life Sciences

atai Life Sciences Announces $50 Million Private Placement Financing

a month ago - By: atai Life Sciences

atai Life Sciences Announces $50 Million Private Placement Financing

a month ago - By: atai Life Sciences

atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression

a month ago - By: atai Life Sciences

atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression

a month ago - By: Bloomberg

Atai Shares Rise on Beckley’s Psychedelic Drug Study Success

2 months ago - By: Yahoo Finance - Mentions: UBS T T-PA

UBS Raised the PT on AT&T (T), Keeps a Buy Rating

2 months ago - By: Yahoo Finance - Mentions: OPK ENTX

Piper Sandler Reiterates a Buy Rating on Opko Health (OPK) With a $3 PT

2 months ago - By: Yahoo Finance

Maxim Group Maintains a Buy on Atai Life Sciences (ATAI) With a $6 Price Target

2 months ago - By: Halper Sadeh LLC - Mentions: LNSR ICAD

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LNSR, ATAI, ICAD on Behalf of Shareholders

2 months ago - By: Halper Sadeh LLC

ATAI Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of Atai Life Sciences N.V. is Fair to Shareholders

2 months ago - By: Bloomberg

Thiel-Backed Psychedelic Drugmaker Atai to Combine With Beckley

2 months ago - By: atai Life Sciences

atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies

2 months ago - By: atai Life Sciences

atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies

2 months ago - By: atai Life Sciences

ATAI LIFE SCIENCES NV (ATAI) Stock News

ATAI Latest News, Press Relases and Analysis

What's going on in today's pre-market session

Top movers in Friday's after hours session

H.C. Wainwright Lifts PT on Atai Life Sciences (ATAI) to $15 From $10

This IonQ Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

This Atai Life Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday

Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia

Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia

Aegis Capital Reaffirms Buy on Atai Life Sciences N.V. (ATAI) with $8 Target

Canaccord Genuity Lifts Atai Life Sciences N.V. (ATAI)’s Price Target To $12, Maintains Buy Rating

Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032

atai Life Sciences Announces $50 Million Private Placement Financing

atai Life Sciences Announces $50 Million Private Placement Financing

atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression

atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression

Atai Shares Rise on Beckley’s Psychedelic Drug Study Success

UBS Raised the PT on AT&T (T), Keeps a Buy Rating

Piper Sandler Reiterates a Buy Rating on Opko Health (OPK) With a $3 PT

Maxim Group Maintains a Buy on Atai Life Sciences (ATAI) With a $6 Price Target

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LNSR, ATAI, ICAD on Behalf of Shareholders

ATAI Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of Atai Life Sciences N.V. is Fair to Shareholders

Thiel-Backed Psychedelic Drugmaker Atai to Combine With Beckley

atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies

atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies

atai Life Sciences to Participate in Upcoming Investor Conferences